Tekmira Pharmaceuticals Corporation and the National Cancer Institute Publish Promising Data Demonstrating the Anti-Tumor Activity of a Novel Cancer Target
VANCOUVER, British Columbia, April 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that promising preclinical data from its collaboration with the National Cancer Institute (NCI) has been published in Oncogene, one of the world's leading cancer journals.